Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer

Docetaxel remains the standard-of-care for men diagnosed with metastatic castrate-resistant prostate cancer (CRPC). However, only approximately 50% of patients benefit from treatment and all develop docetaxel-resistant disease. Here, we characterize global perturbations in tyrosine kinase signaling...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2014-01, Vol.13 (1), p.190-201
Hauptverfasser:	Lee, Brian Y, Hochgräfe, Falko, Lin, Hui-Ming, Castillo, Lesley, Wu, Jianmin, Raftery, Mark J, Martin Shreeve, S, Horvath, Lisa G, Daly, Roger J
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis - drug effects Cell Line, Tumor Cell Survival - drug effects Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Focal Adhesion Kinase 1 - genetics Focal Adhesion Kinase 1 - isolation & purification Humans Male Phosphoproteins - isolation & purification Phosphoproteins - metabolism Phosphorylation - drug effects Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - pathology Protein-Tyrosine Kinases - antagonists & inhibitors Proteomics Pyrimidines - administration & dosage Signal Transduction Sulfonamides - administration & dosage Taxoids - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!